PNC-27
Aliases: p53(12-26) membrane-active peptide
Last verified: 2026-09-24
The short version
PNC-27 is the most dangerous category of gray-market selling: a cancer promise. Its story has a beginning (p53 membrane biology is real science) and a middle (in vitro lysis of tumor cells), but no end — no human study, no independent replication, no understanding of systemic selectivity. Cancer patients are the most vulnerable audience on the internet: every day of delaying real treatment is measured in lives. Every vial of PNC-27 sold 'for research purposes' is a moral problem, not just a pharmacological one. If there is one entry in this catalog to read as a responsible warning, it is this one.
Identity & type
- Molecular type
- peptide
- Molecular weight
- ~3.2 kDa
- Origin
- Designed around the p53(12-26) sequence with membrane-active properties; synthetic.
Mechanism of action
A 27-amino-acid peptide derived from a p53 domain motif that binds membrane cholesterol independently of the cell's p53 status; it is claimed that on cells with mutant p53 it forms pores and induces membrane death — an 'anticancer peptide' that supposedly attacks only tumor cells.
not confirmed in humans
Dosing & routes
Official / clinical context
No official context exists; oncology treatment is among the most strictly regulated areas of medicine.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Banned or extremely marginal in serious communities; where it appears, it involves desperate situations — precisely those where delayed diagnosis is most expensive.
Unverified self-reports. Not medical advice. Not endorsement.
Protocol — official vs community
Official / label
No approved protocol exists — preclinical agent. PNC-27 has only in vitro and xenograft dosing (µg–mg/kg); it has never been administered to a human in a registered study.
Duration: —
The claimed tumor-selectivity mechanism (pore formation on cholesterol-rich membranes of p53-mutant cells) is contested — pore-forming peptides do not cleanly discriminate tumor from healthy membranes.
Community (anecdotal)
No standardized community protocol exists. Occasional 'research use' claims circulate without any dose consensus, and no credible source has established a human dose.
- Cycle:
- —
- Break:
- —
PNC-27's internet presence is driven by its anticancer marketing narrative, not by any community of actual users. The honest summary is that nothing resembling a validated protocol exists.
Human evidence
None — not a single registered trial.
Preclinical evidence
Interesting in vitro, modest in vivo: a few xenograft studies from the same group; without independent replication or comparative data with standard therapies.
Known risks
- Delaying proven oncology treatmentcharacterized
- Non-selective membrane toxicity (theoretical, based on mechanism)theoretical
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Systemic selectivity and safety — the mechanism's basic assumption is unproven
Frequently asked questions
References
- PNC-27 p53-derived membrane-active peptide — preclinical studies (single-group literature)